Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMAR: Crizotinib + Bevacizumab in ALK/ROS1/MET+ Lung Adenocarcinoma
NCT02946359Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizotinib and bevacizumab in lung adenocarcinoma, sponsored by Chinese PLA General Hospital. Primary endpoint: Progression-Free Survival up to 100 months. Status: unknown.
02
Drugs
crizotinibbevacizumab
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02946359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946359.